Dr. Paul Rennert is an experienced biotechnology executive and seasoned researcher with extensive strategic and leadership experience. Dr. Rennert has demonstrated success in bench to IND development of small molecule and biologic drugs for oncology, autoimmunity, chronic inflammation and fibrosis, primarily as a Principal Scientist at Biogen. Dr. Rennert’s recent accomplishments include working intensively with CoStim Pharmaceuticals' executive team to prioritize and build the company's immunotherapy portfolio, which was acquired in 2014 by Novartis. He is also the editor of, Novel Immunotherapeutic Approaches to the Treatment of Cancer: Drug Development and Clinical Application.